TY - JOUR
T1 - Novel pharmacological treatments for generalized anxiety disorder
T2 - Pediatric considerations
AU - Sonmez, A. Irem
AU - Almorsy, Ammar
AU - Ramsey, Laura B.
AU - Strawn, Jeffrey R.
AU - Croarkin, Paul E.
N1 - Funding Information:
Dr. Croarkin receives research support from the NIH. He has received research grant support from Pfizer Inc.; equipment support from Neuronetics Inc.; and received supplies and genotyping services from Assurex Health Inc. for investigator‐initiated studies. He is the primary investigator for a multicenter study funded by Neuronetics Inc. and a site primary investigator for a study funded by NeoSync Inc. He also serves as a paid consultant for Procter & Gamble Company and Myriad Neuroscience. Dr. Ramsey has received research support from the NIH (NICHD) and BTG International Ltd. Dr. Strawn has received research support from the NIH (NIMH/NIEHS), Patient‐Centered Outcomes Research (PCORI), Allergan, Otzuka, and Neuronetics. He has received material support from Myriad Genetics and receives royalties from the publication of two textbooks (Springer). He serves as an author for . He is also an Associate Editor for . He has received honoraria from CMEology and Neuroscience Educational Institute. The remaining authors declare that there are no conflict of interests. UpToDate Current Psychiatry
Funding Information:
We thank Anosha Zanjani for her expertise and assistance with the creation of Figures 1 and 2 . We thank Danielle Gerberi for her help with the literature search. The preparation of this manuscript was supported by the National Institutes of Health (NIH) under awards R01 MH113700 (P. E. C.) and R01 HD098757 (J. R. S.). The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The supporters had no role in the literature review, interpretation, or publication.
Publisher Copyright:
© 2020 Wiley Periodicals LLC
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/8/1
Y1 - 2020/8/1
N2 - Background: Pediatric anxiety disorders such as generalized anxiety disorder (GAD) are common, impairing, and often undertreated. Moreover, many youth do not respond to standard, evidence-based psychosocial or psychopharmacologic treatment. An increased understanding of the gamma-aminobutyric acid (GABA) and glutamate neurotransmitter systems has created opportunities for novel intervention development for pediatric GAD. Methods: This narrative review examines potential candidates for pediatric GAD: eszopiclone, riluzole, eglumegad (LY354740), pimavanserin, agomelatine. Results: The pharmacology, preclinical data, clinical trial findings and known side effects of eszopiclone, riluzole, eglumegad (LY354740), pimavanserin, agomelatine, are reviewed, particularly with regard to their potential therapeutic relevance to pediatric GAD. Conclusion: Notwithstanding numerous challenges, some of these agents represent potential candidate drugs for pediatric GAD. Further treatment development studies of agomelatine, eszopiclone, pimavanserin and riluzole for pediatric GAD also have the prospect of informing the understanding of GABAergic and glutamatergic function across development.
AB - Background: Pediatric anxiety disorders such as generalized anxiety disorder (GAD) are common, impairing, and often undertreated. Moreover, many youth do not respond to standard, evidence-based psychosocial or psychopharmacologic treatment. An increased understanding of the gamma-aminobutyric acid (GABA) and glutamate neurotransmitter systems has created opportunities for novel intervention development for pediatric GAD. Methods: This narrative review examines potential candidates for pediatric GAD: eszopiclone, riluzole, eglumegad (LY354740), pimavanserin, agomelatine. Results: The pharmacology, preclinical data, clinical trial findings and known side effects of eszopiclone, riluzole, eglumegad (LY354740), pimavanserin, agomelatine, are reviewed, particularly with regard to their potential therapeutic relevance to pediatric GAD. Conclusion: Notwithstanding numerous challenges, some of these agents represent potential candidate drugs for pediatric GAD. Further treatment development studies of agomelatine, eszopiclone, pimavanserin and riluzole for pediatric GAD also have the prospect of informing the understanding of GABAergic and glutamatergic function across development.
KW - agomelatine
KW - anxiety
KW - drug development
KW - eglumegad (LY354740)
KW - eszopiclone
KW - generalized anxiety disorder
KW - pediatric
KW - pimavanserin
KW - riluzole
UR - http://www.scopus.com/inward/record.url?scp=85085022152&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085022152&partnerID=8YFLogxK
U2 - 10.1002/da.23038
DO - 10.1002/da.23038
M3 - Review article
C2 - 32419335
AN - SCOPUS:85085022152
VL - 37
SP - 747
EP - 759
JO - Depression and Anxiety
JF - Depression and Anxiety
SN - 1091-4269
IS - 8
ER -